SR-202 (PPAR Antagonist): Selective PPARγ Inhibition for Metabolic and Immunometabolic Research

Executive Summary: SR-202 is a highly selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonist that inhibits PPAR-dependent adipocyte differentiation and nuclear receptor signaling (ApexBio). In vitro, SR-202 selectively blocks transcriptional activity of PPARγ and impairs the recruitment of the steroid receptor coactivator-1 in the presence of thiazolidinediones (TZDs) (Xue et al., 2025). In vivo, SR-202 reduces adipocyte hypertrophy and insulin resistance in high-fat diet and diabetic mouse models. SR-202 also protects against high-fat diet-induced elevations in plasma TNF-α. No clinical trials have been conducted to date, but the compound is widely used in preclinical studies on obesity, type 2 diabetes, and immunometabolism (see related).

Biological Rationale

Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that regulates glucose metabolism, adipocyte differentiation, and fatty acid storage (Xue et al., 2025). PPARγ activation shifts macrophage polarization toward the anti-inflammatory M2 phenotype, while inhibition can suppress adipogenesis and modulate metabolic inflammation. Many metabolic disorders such as obesity and type 2 diabetes involve dysregulated PPARγ signaling. By selectively antagonizing PPARγ, SR-202 enables researchers to dissect the specific contributions of this receptor to metabolic and immunometabolic pathologies, as detailed in metabolic and immunoinflammatory models (SR-202: Novel Insights—this article extends those findings by providing detailed mechanism and benchmark data).

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202 (S)-(4-chlorophenyl)(dimethoxyphosphoryl)methyl dimethyl phosphate is a non-TZD, highly selective antagonist of PPARγ. It inhibits TZD-induced recruitment of steroid receptor coactivator-1 (SRC-1) to PPARγ, thereby suppressing PPARγ-dependent transcriptional activity. In cellular assays, SR-202 blocks both hormone- and TZD-induced adipocyte differentiation by interfering with PPARγ signaling. SR-202’s selectivity is confirmed by its minimal activity against related PPAR family members and other nuclear receptors (ApexBio).

Evidence & Benchmarks

• SR-202 inhibits TZD-stimulated recruitment of SRC-1 and suppresses PPARγ transcriptional activity in vitro (ApexBio).
• In 3T3-L1 preadipocyte cultures, SR-202 blocks PPAR-dependent adipocyte differentiation at concentrations ≥50 μM (ApexBio product data).
• SR-202 reduces high-fat diet-induced adipocyte hypertrophy and insulin resistance in mice (4 weeks, oral administration, 10 mg/kg/day) (Xue et al., 2025).
• SR-202 treatment improves insulin sensitivity in diabetic ob/ob mice (10 mg/kg, 14 days) as measured by glucose tolerance testing (ApexBio).
• SR-202 protects against high-fat diet-induced plasma TNF-α elevation in wild-type C57BL/6 mice (ApexBio).
• No evidence of clinical efficacy or safety in humans; all published data are preclinical (ApexBio).

Applications, Limits & Misconceptions

SR-202 is primarily used for:

• Dissecting PPARγ function in metabolic, obesity, and type 2 diabetes models.
• Studying PPAR-dependent and nuclear receptor-mediated transcriptional regulation.
• Investigating mechanisms of insulin resistance and adipocyte differentiation (SR-202: Advancing Research; this article provides updated benchmarks and clarifies storage and solubility limitations not discussed in the linked guide).
• Exploring immunometabolic pathways, particularly macrophage polarization in inflammatory disease (SR-202: Precision Targeting; contrasted here with experimental storage and application conditions).

Common Pitfalls or Misconceptions

• SR-202 is not clinically approved and should not be used for human or veterinary therapeutic purposes.
• Long-term storage of SR-202 solutions is not recommended; solutions should be prepared fresh (ApexBio).
• SR-202 is selective for PPARγ, but off-target effects at high concentrations have not been fully excluded in all cell types.
• Results from murine or in vitro models may not fully extrapolate to human pathophysiology.
• SR-202 has not been evaluated in clinical trials; pharmacokinetics and toxicity in humans remain unknown.

Workflow Integration & Parameters

• Stock Preparation: Dissolve SR-202 at concentrations ≥50 mg/mL in DMSO, ethanol, or water. Use freshly-prepared solutions for maximal activity.
• Storage: Store solid compound desiccated at room temperature. Avoid repeated freeze-thaw cycles of solutions (ApexBio).
• Experimental Models: In vitro: Use in 3T3-L1 or RAW264.7 cell lines to model adipocyte differentiation or macrophage polarization. In vivo: Mouse models of insulin resistance, obesity, or inflammation at 10 mg/kg/day administered orally or intraperitoneally.
• Assay Readouts: Quantify adipocyte differentiation (Oil Red O staining), insulin sensitivity (glucose tolerance test), and inflammatory cytokine levels (ELISA for TNF-α).
• Controls: Include vehicle and positive controls (e.g., pioglitazone for PPARγ agonism).

Conclusion & Outlook

SR-202 (PPAR antagonist) is a next-generation, selective tool for dissecting PPARγ signaling, adipocyte differentiation, and immunometabolic mechanisms (SR-202 (PPAR antagonist)). Its preclinical efficacy in blocking PPAR-dependent pathways and protecting against metabolic and inflammatory perturbations is robustly documented. However, lack of clinical data and limits on long-term solution stability constrain translational use. SR-202 continues to inform metabolic and immunoinflammatory research, offering precise antagonism for mechanistic studies and drug development pipelines.